Q3 EPS Estimates for FibroBiologics Boosted by HC Wainwright

FibroBiologics Inc. (NASDAQ:FBLG) – HC Wainwright raised their Q3 2026 earnings estimates for shares of FibroBiologics in a report issued on Tuesday, August 4th. HC Wainwright analyst M. Caufield now forecasts that the company will earn ($0.63) per share for the quarter, up from their prior estimate of ($0.94). HC Wainwright currently has a “Buy” rating and a $6.00 price objective on the stock. The consensus estimate for FibroBiologics’ current full-year earnings is ($4.01) per share. HC Wainwright also issued estimates for FibroBiologics’ Q4 2026 earnings at ($0.63) EPS, FY2026 earnings at ($3.00) EPS, FY2027 earnings at ($3.25) EPS, FY2028 earnings at ($4.00) EPS, FY2029 earnings at ($4.89) EPS and FY2030 earnings at ($4.23) EPS.

FibroBiologics (NASDAQ:FBLG) last released its quarterly earnings data on Friday, July 31st. The company reported ($0.66) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.93) by $0.27.

Several other research analysts have also recently issued reports on the company. Weiss Ratings raised FibroBiologics from a “sell (e)” rating to a “sell (e+)” rating in a research report on Friday, July 24th. Wall Street Zen raised FibroBiologics from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 13th. Maxim Group cut FibroBiologics from a “buy” rating to a “hold” rating in a research note on Monday, May 4th. Finally, Deutsche Bank Aktiengesellschaft downgraded FibroBiologics to an “underperform” rating in a report on Tuesday. One equities research analyst has rated the stock with a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Reduce” and an average price target of $73.00.

FibroBiologics Price Performance

FibroBiologics stock opened at $0.87 on Thursday. FibroBiologics has a 1-year low of $0.62 and a 1-year high of $12.80. The stock has a market cap of $5.78 million, a PE ratio of -0.17 and a beta of 1.20. The stock’s fifty day moving average is $0.86 and its two-hundred day moving average is $2.85.

Institutional Investors Weigh In On FibroBiologics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. AQR Capital Management LLC purchased a new position in shares of FibroBiologics during the first quarter worth approximately $29,000. XTX Topco Ltd increased its stake in FibroBiologics by 160.0% in the second quarter. XTX Topco Ltd now owns 45,945 shares of the company’s stock valued at $29,000 after purchasing an additional 28,276 shares during the period. Marshall Wace LLP acquired a new stake in shares of FibroBiologics during the second quarter worth about $49,000. Cerity Partners LLC raised its stake in FibroBiologics by 37.2% during the 2nd quarter. Cerity Partners LLC now owns 128,109 shares of the company’s stock valued at $80,000 after acquiring an additional 34,702 shares during the last quarter. Finally, Jane Street Group LLC acquired a new stake in FibroBiologics during the 2nd quarter worth approximately $60,000.

FibroBiologics Company Profile

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc was incorporated in 2021 and is based in Houston, Texas.